The researches expect new possibilities for the ovarian cancer screening to be offered by the novel cancer marker, HE4, used to date along with CA125 mainly in the diagnostics of pathological developments within the adnexa [1–10]. The gene discussed is WFDC2; the disease is ovarian carcinoma.